In the race to capitalize on patient-driven interest in stem cells, biologic solutions and “regeneration” of a more vital, healthy and functional body, there has been an explosion of offerings that lack scientific controls, validity and meaningful evidence.
ORTHOWORLD estimates Stryker's 2Q18 orthopaedic revenue at US $1,747.8MM, +8.0% from 2Q17, and 1H18 revenue at $3,472.6MM, +7.5% vs. 1H17. Trauma and Extremities Joint Recon remain high performers, with Interventional and Tritanium products contributing to strong spine segment growth.
Extremity Medical's 2018 product launches will include the Omni foot plating system, AlignX lateral plates for tibiotalar and tibiotalar-calcaneus fusion, Charcot-specific plates and the Freedom next-gen fixation system.
DiscGenics closed a US $14MM Series B financing. Funds will support regulatory approvals and manufacturing ramp-up for Phase III clinical and commercial production of its cell therapy for treatment of degenerative disc disease.
Creative Medical filed two patent applications regarding use of immune system cells to stimulate blood vessel formation for the treatment of lower back pain, and to support intradiscal stem cell administration to treat degenerative disc disease.
Three-month safety data from a Phase I clinical trial in China for Cellular Biomedicine's AlloJoin™ off-the-shelf allogeneic stem cell therapy in the treatment of knee osteoarthritis demonstrated a safety and tolerability profile of AlloJoin in the three doses tested, with adverse events similar to that of earlier autologous trials. The trial is slated for completion in 3Q17.
OSTEOGROW, an EU-funded collaborative research project, is investigating a new bone regeneration therapy based on autologous blood + BMP-6 for use in applications requiring partial bone replacement, without the need for secondary interventions.
MiMedx signed a definitive agreement to acquire Stability Biologics for US $10MM in cash and stock. Stability Biologics provides human tissue products for the surgical, spine and orthopaedic industries. The transaction is expected to close in early 1Q16.